"Immune Monitoring : T cell mucin 1-specific responses
Analysis of three patients after the first three doses of CVac has shown a mucin 1-specific T cell response while no response was observed in normal healthy volunteers nor untreated patients ."
An early lead on the ICS result for the full 7 cohort trial, which could be out any time.
This seems to be just what we're hoping for, potential to move into other treatment markets.
ann out , page-4
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.005(1.61%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.5¢ | $694.0K | 2.223M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 22530 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 176372 | 4 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |